Biliary tract disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 27 May 2026 04:04:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Biliary tract disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Durvalumab and Chemotherapy for Patients with Advanced Biliary Tract Cancer https://clinicaltrials.eu/trial/study-on-durvalumab-and-chemotherapy-for-patients-with-advanced-biliary-tract-cancer/ Thu, 14 May 2026 05:09:25 +0000 https://clinicaltrials.eu/trial/study-on-durvalumab-and-chemotherapy-for-patients-with-advanced-biliary-tract-cancer/ This clinical trial is focused on studying the treatment of Advanced Biliary Tract Cancers, which are cancers that occur in the bile ducts, gallbladder, and the area where the bile duct meets the small intestine. The study will use a medication called Durvalumab, which is a type of drug that helps the immune system fight cancer. Durvalumab will be combined with a chemotherapy treatment that includes Gemcitabine, a drug that helps stop the growth of cancer cells. Other chemotherapy drugs that may be used in combination include Cisplatin, Oxaliplatin, Carboplatin, and Inflectra (infliximab). The purpose of the study is to assess the safety of using Durvalumab with Gemcitabine-based chemotherapy.

Participants in the study will receive the treatment through an infusion, which means the medication will be given directly into a vein. The study will follow a single-arm, open-label design, meaning all participants will receive the same treatment, and both the participants and the researchers will know what treatment is being given. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effects of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatment.

The study aims to gather information on how well the treatment works and any side effects that may occur. This information will help doctors understand the potential benefits and risks of using Durvalumab in combination with chemotherapy for treating advanced biliary tract cancers. Participants will be closely monitored throughout the study to ensure their safety and well-being. The study is expected to continue until 2026, with recruitment starting in 2024.

]]>